Abstract: Three HBV isolates (8.3%) were identified with drug resistance mutations to lamivudine, entericavir, telbivudine and tenofovir, which are amino acid substitutions in the HBV polymerase gene at positions L180M, T184A, M204V.
Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region.
Method: According to the most recent clinical practice guidelines of the European Association for the Study of the Liv
Result: Overall, rtL180M, rtA181T/V, rtT184G/S, rtS202G/I, rtM204I, rtM204V, rtN236T, and rtM250V were more frequently detected in genotypes A (13.9%), C (0.8%), D (0.1%), H (3.8%), G (25%), A (13.1%), B (0.7%), and C (0.1%), respectively.
Table: L180M
Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.
Abstract: CONCLUSION: An rtL180M/T184L/A200V/M204V mutant with moderate resistance to TDF monotherapy was selected during sequential nucleoside analogue (NA) treatment in a stepwise manner.
Abstract: In vitro phenotyping demonstrated that the rtL180M/T184L/A200V/M204V mutant had moderate resistance to TDF treatment, with a 4.52-fold higher half maximal effective concentration than that of wild-type virus.
Abstract: METHODS AND RESULTS: Here, we report viral rebound in a patient with chronic hepatitis B who underwent TDF monotherapy and harboured a quadruple mutant consisting of cla
Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis.
Abstract: None of the known tenofovir resistance mutations (M240V/I, L180M, A194T, Result: No mutations known to cause tenofovir resistance (L180M, A181I/V, A194T, M204V/I, V214A, Q215S, N236T) or lamuvudine (3TC) resistance (L80V/I, I169T, V173L, L180M, A181T, T184S, M204V/I/S, Q215S) were observed.
Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing.
PMID: 31189581
2019
Journal of clinical microbiology
Introduction: For instance, I195M in the S protein (sI195M) and sW196S can produce rtM204I and rtL180M/rtM204I in RT, which could confer resistance to LMV.
Introduction: For instance, M204V/I in RT (rtM204V/I) is a classical lamivudine (LMV) resistance mutation, which also greatly reduces susceptibility to telbivudine (LdT); rt
Hepatitis B virus reverse transcriptase polymorphisms between treated and treatment-naive chronically infected patients.
Abstract: Drug resistance conferring substitutions (DRCSs) were rtL180M (22/98), rtA194V (11/98), rtM204V (1/98), and rtM204I (11/98).
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Introduction: These two categories are known as classical mutations, which include: (i) M204I/V mutation, which associates with LAM or LDT resistance; (ii) N236T or A181T/V mutations, which associate with ADV resistance; (iii) M204V + L180M and either T184A/G/I/L/S or S202G or M250V to develop resistance to ETV.
Result: In case three, multiple mutation patterns were observed from L180M + M204V + I224V + N238H to L180M + M204V + T184S
[HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
Abstract: Primary/secondary drug mutations (rtM204I/V, rtI169S, rtL180M, rtT184L, rtA194V, rtM204I/rtL91I, rtQ149K, rtQ215H/S, rtN238D) were detected in 38 (45.2%) of the patients.
Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy.
PMID: 30906435
2019
Experimental and therapeutic medicine
Result: Common and frequent mutations identified in the cohort of the present study included rtL80V/I, rtV84M, rtL91I, rtN118H/D/T, rtT128A, rtL180M, rtT184L/S/A, rtV191I, rtS202G, rtV207I/M, rtS213T
Patterns of hepatitis B virus S gene escape mutants and reverse transcriptase mutations among genotype D isolates in Jordan.
Result: The first patient was a male with history of treatment with lamivudine who had mutations at established drug resistance positions: L180M, T184A, M204V which confer resistance to lamivudine, entecavir and telbivudine.
Result: The second patient was a female with unknown history of treatment who had mutations at established drug resistance positions: L180M, M204V which confer resistance to lamivudine, telbivudine and partial resistance to entecavir.
Result: The third patient was a male with history of treatment with lamivudine who had mutations at established drug resistance positions: V173L, L180M, M204V which confer resistance to lamivudine, telbivudine and partial resistance to entecavir.
HBV mutation literature information.
PMID: 
2020
Klinicheskaia laboratornaia diagnostika
Browser Board
Co-occurred Entities
Filtrator
ViMRT